Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 4/20 | 0.66 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878027 | 1.00 | NAAA (0.66) | NAAATRPV1APPMEN1KMT2A | |
| SCHEMBL9346636 | 0.86 | TRPV1 (0.56) | NAAATRPV1APPMEN1KMT2A | |
| SCHEMBL9345351 | 0.86 | TRPV1 (0.56) | NAAATRPV1APPMEN1KMT2A | |
| SCHEMBL9350012 | 0.86 | TRPV1 (0.56) | NAAATRPV1APPMEN1KMT2A | |
| SCHEMBL5704957 | 0.86 | NAAA (0.59) | NAAA | |
| SCHEMBL4881044 | 0.86 | NAAA (0.59) | NAAA | |
| SCHEMBL4886844 | 0.86 | NAAA (0.59) | NAAA | |
| SCHEMBL5705007 | 0.86 | NAAA (0.59) | NAAANPSR1 | |
| SCHEMBL2121870 | 0.86 | NAAA (0.59) | NAAANPSR1 | |
| SCHEMBL4876904 | 0.86 | NAAA (0.59) | NAAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171617-A1 | 3,4-Dihydroxymandelic acid alkylamides and use thereof | HAARMANN & REIMER GMBH (DE) | 2003-09-11 | — | — | US | claimed |
| US-20030171617-A1 | 3,4-Dihydroxymandelic acid alkylamides and use thereof | HAARMANN & REIMER GMBH (DE) | 2003-09-11 | — | — | US | disclosed |
| CN-1437577-A | 3, 4-dihydroxymandelic acid alkylamides and use thereof | HAARMANN & REIMER GMBH (DE) | 2003-08-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171617-A1 | 3,4-Dihydroxymandelic acid alkylamides and use thereof | HNMT, HTR2A, HTR2C | NAAA 33/4885TRPV1 382/4885APP 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.